Objective To analyze the clinical characteristics of Mycobacterium tuberculosis (Mtb) infection of the sternum after cardiac surgery. Methods A computerized search was conducted in PubMed, Web of Science, Wanfang, and CNKI databases for published case reports of post-cardiac surgery sternal Mtb infections up to July 18, 2023. Two researchers independently screened the included cases, extracted relevant data, and analyzed clinical features. Results A total of 15 articles involving 26 patients were included, comprising 16 males and 10 females, with a mean age of (61.9±15.6) years (range 5-80). Previous surgical histories included coronary artery bypass grafting (14 patients, 53.8%), valve surgery (8 patients, 30.8%), congenital heart disease surgery (3 patients, 11.5%), and aortic surgery (2 patients, 7.7%). The main symptoms and signs were wound abscesses and poor healing, often accompanied by pain, with or without redness and swelling, while systemic symptoms such as low-grade fever, night sweats, and weight loss were typically absent. The median time for infection to be discovered in 13 patients after surgery was 10.0 (3.0, 13.0) months, and the median interval between infection discovery and diagnosis in 9 patients was 3.0 (2.0, 6.0) months. The primary diagnostic methods included Mtb culture, histopathology, and acid-fast staining of debrided bone tissue or pus. One patient died of cardiac arrest before diagnosis. Among the 25 diagnosed patients, 13 received only antitubercular therapy (11 of whom had undergone surgical treatment before diagnosis), while 12 received combined antitubercular and surgical treatment. All 25 patients were successfully cured, with antitubercular therapy lasting 6-12 months. Conclusion Post-cardiac surgery sternal Mtb infection has a prolonged latency period and poses significant diagnostic challenges, leading to high rates of missed and misdiagnosed cases. Timely diagnosis and treatment can markedly improve prognosis.
Objective To compare the early outcomes of domestic third-generation magnetically levitated left ventricular assist device (LVAD) with or without concomitant mitral valvuloplasty (MVP). Methods The clinical data of 17 end-stage heart failure patients who underwent LVAD implantation combined with preoperative moderate to severe mitral regurgitation in Fuwai Central China Cardiovascular Hospital from May 2018 to March 2023 were retrospectively analyzed. The patients were divided into a LVAD group and a LVAD+MVP group based on whether MVP was performed simultaneously, and early outcomes were compared between the two groups. Results There were 4 patients in the LVAD group, all males, aged (43.5±5.9) years, and 13 patients in the LVAD+MVP group, including 10 males and 3 females, aged (46.8±16.7) years. All the patients were successful in concomitant MVP without mitral reguragitation occurrence. Compared with the LVAD group, the LVAD+MVP group had a lower pulmonary artery systolic pressure and pulmonary artery mean pressure 72 h after operation, but the difference was not statistically different (P>0.05). Pulmonary artery systolic pressure was significantly lower 1 week after operation, as well as pulmonary artery systolic blood pressure and pulmonary artery mean pressure at 1 month after operation (P<0.01). There was no statistically significant difference in blood loss, operation time, cardiopulmonary bypass time, aortic cross-clamping time, mechanical ventilation time, or ICU stay time between the two groups (P>0.05). The differences in 1-month postoperative mortality, acute kidney injury, reoperation, gastrointestinal bleeding, and thrombosis and other complications between the two groups were not statistically significant (P>0.05). Conclusion Concomitant MVP with implantation of domestic third-generation magnetically levitated LVAD is safe and feasible, and concomitant MVP may improve postoperative hemodynamics without significantly increasing perioperative mortality and complication rates.
Objective To compare and analyze the early- to mid-term outcomes of transcatheter aortic valve replacement (TAVR) combined with percutaneous coronary intervention (PCI) versus surgical aortic valve replacement (SAVR) combined with coronary artery bypass grafting (CABG) for the treatment of significant aortic stenosis (AS) and coronary artery disease (CAD). Methods The data of patients with significant AS and CAD who underwent surgical treatment at Central China Fuwai Hospital of Zhengzhou University from January 2018 to July 2023 were collected. These patients were divided into a TAVR+PCI group and a SAVR+CABG group according to the operation method. Propensity score matching (PSM) was used to select patients with close clinical baseline characteristics, and the early- to mid-term outcomes of the two groups were compared. Results A total of 272 patients were enrolled, including 208 males and 64 females, with a mean age of 64.16±8.24 years. There were 47 patients in the TAVR+PCI group and 225 patients in the SAVR+CABG group. After 1∶1 PSM, 32 pairs were selected. There was no statistical difference in baseline data between the two groups (P>0.05). Compared with the SAVR+CABG group, the TAVR+PCI group had significantly shorter operative time, mechanical ventilation time, ICU stay, postoperative hospital stay, and less intraoperative bleeding, and significantly lower postoperative transfusion and complete revascularization rates (P<0.05). The differences in the rates of postoperative in-hospital death, myocardial infarction, stroke, and other complications between the two groups were not statistically significant (P>0.05), and the differences in the rates of severe perivalvular leakage, death, or readmission in the mid-term follow-up were not statistically significant (P>0.05). Conclusion In patients with significant AS and CAD, the early- and mid-term rates of death and complications were similar between those treated with TAVR+PCI and SAVR+CABG, and TAVR+PCI is a safe alternative to SAVR+CABG.